Advances in umbilical cord blood transplant: an overview of the 12th International Cord Blood Symposium, San Francisco, 5–7 June 2014

References

• Goldman SA, Nedergaard M, Windrem MS. Glial progenitor cell-based treatment and modeling of neurological disease. Science 2012;338:491–495.
   PubMed Web of Science ®Google Scholar
• Tracy ET, Zhang CY, Gentry T, et al. Isolation and expansion of oligodendrocyte progenitor cells from cryopreserved human umbilical cord blood. Cytotherapy 2011;13:722–729.
   PubMed Web of Science ®Google Scholar
• Tracy E, Aldrink J, Panosian J, et al. Isolation of oligodendrocyte-like cells from human umbilical cord blood. Cytotherapy 2008; 10:518–525.
   PubMed Web of Science ®Google Scholar
• Cotten CM, Murtha AP, Goldberg RN, et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr 2014;164:973–979.
   PubMed Web of Science ®Google Scholar
• Prasain N, Meador JL, Yoder MC. Phenotypic and functional characterization of endothelial colony forming cells derived from human umbilical cord blood. J Vis Exp 2012;(62): pii: 3872.
   PubMedGoogle Scholar
• Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 2011;117:4773–4777.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Eapen M, Ruggeri A et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant 2014;20:816–822.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2013;19:1355–1360.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Ooi J, et al. Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2014;20:1150–1155.
   PubMed Web of Science ®Google Scholar
• Gutman JA, Myint H, Lee CK, et al. Chronic graft versus host disease and immunosuppression burden is significantly lower following adult cord blood transplantation versus matched unrelated donor transplantation. Biol Blood Marrow Transplant 2014;20(Suupl. 2):S35.
   Google Scholar
• Dahi PB, Ponce D, Byam C, et al. Prospective evaluation of alternative donor availability in 708 patients: improved allograft access with enlarging CB inventory for all patients including racial and ethnic minorities. Blood 2013;122(Suppl. 1): Abstract 162.
   Google Scholar
• Brunstein C, Burns LJ, Wang T et al. Alternative donor transplantation for adults with lymphoma: comparison of umbilical cord blood versus 8/8 HLA-matched donor (URD) versus 7/8 URD. Blood 2013;122(Suppl. 1): Abstract 161.
   PubMed Web of Science ®Google Scholar
• Rodrigues CA, Rocha V, Dreger P, et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica 2014;99:370–377.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 2014;124:3121–3128.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Brunstein CG, McKenna D, et al. Safety and exploratory efficacy of ex vivo expanded umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) using cytokines and stem-regenin 1 (SR1): interim results of a phase 1/2 dose escalation clinical study. Blood 2013;122(Suppl. 1): Abstract 698.
   Google Scholar
• de Lima M, McMannis J, Gee A et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008;41:771–778.
   PubMed Web of Science ®Google Scholar
• de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012;367:2305–2315.
   PubMed Web of Science ®Google Scholar
• Robinson SN, Thomas MW, Simmons PJ, et al. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 2014;16:84–89.
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Hoggatt J, O’Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 2012;18:1786–1796.
   PubMed Web of Science ®Google Scholar
• Velez de Mendizabal N, Strother RM, Farag SS, et al. Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation. Clin Pharmacokinet 2014;53: 247–259.
   PubMed Web of Science ®Google Scholar
• Farag SS, Srivastava S, Messina-Graham S, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 2013;22:1007–1015.
   PubMed Web of Science ®Google Scholar
• Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010;16:232–236.
   PubMed Web of Science ®Google Scholar
• Delaney C, Milano F, Heimfeld S, et al. Dose dependent enhancement of neutrophil recovery by infusion of notch ligand ex vivo expanded cord blood progenitors: results of a multi-center phase I trial. Blood 2013;122(Suppl. 1): Abstract 297.
   Google Scholar
• van Besien K, Artz A, Zhang M-J, et al. Haplo+ cord transplantation: rapid neutrophil and platelet recovery and improved long-term survival compared to double umbilical cord blood (UCB) transplantation—a case-cohort analysis. J Clin Oncol 2014;32(5 Suppl.): Abstract 7004.
   Google Scholar
• Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 2014;123:133–140.
   PubMed Web of Science ®Google Scholar
• Gragert L, Maiers M, Williams E, et al. Modeling effective patient-donor matching for hematopoietic transplantation in United States populations. Hum Immunol 2010;71(Suppl.):S114.
   Google Scholar
• Page KM, Mendizabal A, Betz-Stablein B, et al. Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality. Transfusion 2014;54:340–352.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Wagner EL, Fraser J et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) study report. Transfusion 2005;45:856–866.
   PubMed Web of Science ®Google Scholar
• Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012;367:805–816.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010;116:2411–2419.
   PubMed Web of Science ®Google Scholar
• Torikai H, Reik A, Soldner F, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 2013;122:1341–1349.
   PubMed Web of Science ®Google Scholar
• Ruutu T, Gratwohl A, de Witte T et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014;49:168–173.
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Blaise D, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014;49:389–396.
   PubMed Web of Science ®Google Scholar
• Van BK. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program 2013;2013:56–62.
   PubMedGoogle Scholar
• Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011;118:6438–6445.
   PubMed Web of Science ®Google Scholar
• Pascal L, Tucunduva L, Ruggeri A, et al. Impact of rabbit anti-thymocyte globulin-containing reduced-intensity conditioning regimens on outcomes of adults undergoing unrelated cord blood transplantation for hematological malignancies. Blood 2013;122 (Suppl. 1): Abstract 412.
   Google Scholar
• Ballen KK. ATG for cord blood transplant: yes or no? Blood 2014;123:7–8.
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Chiesa R, Amrolia PJ, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2014;123:126–132.
   PubMed Web of Science ®Google Scholar
• Ponce DM, Gonzales A, Lubin M, et al. Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant 2013;19:904–911.
   PubMed Web of Science ®Google Scholar
• Ponce D, Harnicar SJ, Devlin S, et al. Intensified mycophenolate mofetil (MMF) dosing every 8 hours is safe from the standpoint of engraftment and may ameliorate severe acute graft-versus-host disease (GVHD) after double-unit cord blood transplantation (CBT). Blood 2013;122(Suppl. 1): Abstract 4600.
   Google Scholar
• Salit RB, Milano F, Utman JA, et al. Umbilical cord blood transplant patients at high risk of graft rejection achieve early full donor chimerism when 300cGy is used in the reduced intensity conditioning regimen. Blood 2013;122(Suppl. 1): Abstract 697.
   Google Scholar
• Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061–1070.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Blazar BR, Miller JS, et al. Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. Biol Blood Marrow Transplant 2013;19:1271–1273.
   PubMed Web of Science ®Google Scholar
• Shah N, Martin-Antonio B, Yang H, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013;8:e76781.
   PubMed Web of Science ®Google Scholar
• Purtil D, Smith K, Meagher R, et al. Analysis of 402 cord blood units to assess factors influencing infused viable CD34 + cell dose: the critical determinant of engraftment. Biol Blood Marrow Transplant 2014;20(Suppl. 2):S59.
   Google Scholar
• Nikiforow S, Li S, Liney D, et al. Impact of umbilical cord unit banking conditions on clinical outcomes in double cord transplant recipients. Blood 2013;122(Suppl. 1):Abstract 695.
   Google Scholar
• Young W. Plasma-depleted versus red cell-reduced umbilical cord blood. Cell Transplant 2014;23:407–415.
   PubMed Web of Science ®Google Scholar